

**VIA FEDERAL EXPRESS****Food and Drug Administration  
555 Winderley Pl., Ste. 200  
Maitland, FL 32751****WARNING LETTER****FLA-01-40**

March 6, 2001

**FACILITY ID # 224016**

Mr. Nick Sacaquini  
CEO-Business Manager  
Medical Diagnostic Center  
280 Dundas Drive  
Jacksonville, Florida 32218

Dear Mr. Sacaquini:

We are writing to you because on January 26, 2001, a representative of the State of Florida, acting in behalf of the Food and Drug Administration (FDA) inspected your facility. This inspection revealed serious regulatory problems involving the mammography at your facility. Under a United States Federal law, the Mammography Quality Standards Act of 1992, your facility must meet specific requirements for mammography. These requirements help protect the health of women by assuring that a facility can perform quality mammography. The inspection revealed the following level 1 and 2 findings at your facility:

Level 1: The interpreting physician, [REDACTED] did not meet the requirement of being certified by a FDA recognized board or having the alternative of two (2) months training in the interpretation of mammograms.

Level 2: The measured fog density in the darkroom is equal to 0.17. It should be less than 0.05.

The interpreting physicians, [REDACTED] and [REDACTED] did not meet the requirement of having initial experience in mammography (read or interpret 240 patient examinations in a 6-month period).

The interpreting physician, [REDACTED], did not meet the requirement of having a minimum of 40 CME credit hours of initial training in mammography.

Nick Sacaquini  
Page 2  
March 6, 2001

The interpreting physician, [REDACTED], did not meet the continuing experience requirement of having read or interpreted 960 patient examinations in a 24-month period.

The specific problems noted above appeared on your MQSA Facility Inspection Report, which was issued to your facility at the close of the inspection. Because these conditions may be symptomatic of serious underlying problems that could compromise the quality of mammography at your facility, they represent a serious violation of the law which may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, placing your facility under a Directed Plan of Correction, charging your facility for the cost of on-site monitoring, assessing civil money penalties up to \$10,000 for each failure to substantially comply with, or each day of failure to substantially comply with, the Standards, suspension or revocation of your facility's FDA certificate, or obtaining a court injunction against further mammography.

It is necessary for you to act on this matter immediately. Please explain to this office in writing within fifteen (15) working days from the date you received this letter:

- the specific steps you have taken to correct all of the violations noted in this letter;
- each step your facility is taking to prevent the recurrence of similar violations;
- equipment settings (including technique factors), raw test data, and calculated final results, where appropriate; and
- sample records that demonstrate proper record keeping procedures, if the findings relate to quality control or other records (Note: Patient names or identification should be deleted from any copies submitted).

Please submit your response to Timothy J. Couzins, Compliance Officer, U.S. Food & Drug Administration, 555 Winderley Place, Suite 200, Maitland, Florida 32751, telephone number (407) 475-4728.

Nick Sacaquini  
Page 3  
March 6 2001

Finally, you should understand that there are many FDA requirements pertaining to mammography. This letter pertains only to findings of your inspection and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA's requirements for mammography facilities by contacting the Mammography Quality Assurance Program, Food and Drug Administration, P.O. Box 6057, Columbia, MD 21045-6057 (1-800-838-7715) or through the Internet at <http://www.fda.gov>.

If you have more specific questions about mammography facility requirements, or about the content of this letter, please feel free to contact D. Janneth Caycedo, Consumer Safety Officer, Boca Raton Resident Post, FDA, at 561-338-5236, extension 23.

Sincerely yours,

A handwritten signature in cursive script, appearing to read "Emma R. Singleton".

Emma R. Singleton  
Director, Florida District